ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor
2009 · Nature · 87 citations
https://doi.org/10.1038/nature08297
D
Diego Alvarado
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
75
Papers
1.9K
Citations
22
h-index
30
i10-index
Diego Alvarado is an academic researcher from Celldex Therapeutics (United States). The author has contributed to research in topics: HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research & Lung Cancer Treatments and Mutations. The author has an h-index of 22, co-authored 64 publications.
ORCID: 0000-0002-5878-1730Papers by this author
worksMonomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
2022 · Nature Communications · 55 citations
https://doi.org/10.1038/s41467-022-31601-z
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
2017 · PLoS ONE · 30 citations
https://doi.org/10.1371/journal.pone.0181356
Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy
2020 · Cancer Immunology Immunotherapy · 29 citations
https://doi.org/10.1007/s00262-020-02610-y
Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering
2022 · Communications Biology · 18 citations
https://doi.org/10.1038/s42003-022-03182-6
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma
2019 · Scientific Reports · 17 citations
https://doi.org/10.1038/s41598-019-45589-y
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat